Millions Logo
home>US Stocks>Galectin Therapeutics
GALT
Galectin TherapeuticsHealthcare
$3.13$-2.37 (-43.07%)in 1 year
As on 13 Nov 2026 at 02:29NASDAQ
52 Week Low: $2.0352 Week High: $7.13

Galectin Therapeutics Share Price Today

Galectin Therapeutics opened lower at $3.28, compared with its previous close of $3.29. In the last trading session, the stock traded between $3.07 and $3.53. It showed a downward intraday trend.

Return calculator

Time Period

An investment of $100 made 5 years ago in Galectin Therapeutics is now worth

$ 108.72

Giving a profit of

$ 8.72 (8.72%)

Invest with $1

Note: Past profits do not guarantee future returns.

Analyst Overview

Buy

Rating from 1 Analysts

Buy
100%
Hold
0%
Sell
0%

Markets Today

Today's Change

$-0.16 (-4.83%)

Day High

$3.53

Day Low

$3.07

Day Open

$3.28

Prev Close

$3.29

Volume

2,02,499

1W Return

-9.46%

1M Return

-19.26%

3M Return

0.19%

6M Return

41.67%

1Y Return

-43.07%

Fundamentals

Market Cap ($ Mn)

316

PE Ratio

-

PB Ratio

-

PEG Ratio

-

ROE

-

ROCE

52.18%

EPS (TTM)

$-0.14

Investment Returns

1 Week

-9.46%

1 Month

-19.26%

3 Months

0.19%

6 Months

41.67%

9 Months

13.44%

Financials

Quarterly
All values in $ Mn
0.0

Mar 25
0.0

Jun 25
0.0

Sep 25
0.0

Dec 25
0.0

Mar 26
0.0

Jun 26

Updates

14Aug

Galectin Therapeutics Q2 Results: EPS misses estimate, losses widen

Galectin Therapeutics missed Q2 EPS estimates by 55.56%, reporting a loss of $(0.14) per share versus the expected $(0.09). Losses widened 16.67% YoY from $(0.12) per share, indicating deteriorating profitability trends compared to the prior year period.

3mo ago
24Jun

HC Wainwright reiterates Buy on Galectin Therapeutics

HC Wainwright & Co. analyst Matthew Keller has reiterated a Buy rating for Galectin Therapeutics. The firm maintains a price target of $11 for the stock.

4mo ago
23Jun

FDA backs Galectin's belapectin for MASH cirrhosis treatment

Galectin Therapeutics Inc. announced positive feedback from the FDA following a Type C meeting, supporting the advancement of belapectin for MASH cirrhosis and portal hypertension. The in-person discussion focused on the regulatory pathway for the drug candidate. This endorsement is a key milestone for the company's efforts to treat advanced liver disease.

4mo ago

Similar Stocks

StockLTPChange %Market CapPE
$547.03-0.16%$1,38,692.89M31.55
$61.05+0.38%$1,31,510.31M14.39
$248.69-0.85%$1,00,625.20M-
$959.41+4.73%$97,505.80M19.64
$977.58+0.62%$61,476.10M38.99
$419.98-0.95%$46,108.31M65.60
$180.70-6.40%$39,083.96M-
$53.87-0.37%$33,618.11M26.24
$70.01+0.81%$31,173.07M32.37
$41.85+1.60%$30,322.88M-
$120.75+1.05%$26,490.14M-
$122.27+1.64%$24,922.54M15.85